Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$1.48
$0.01(0.85%)
At close: 4:00 PM EDT
$1.48
$0.01(0.85%)
Day’s Range― - ―
52-Week Range$0.89 - $9.35
Previous Close$0.36
Volume124.96K
Average Volume (3M)232.62K
Market Cap
$28.85M
Enterprise Value$13.97M
Total Cash (Recent Filing)$6.53M
Total Debt (Recent Filing)$7.89M
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Dec 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.58
Shares Outstanding17,588,987
10 Day Avg. Volume146,853
30 Day Avg. Volume232,621
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-2.17
Enterprise Value/Market Cap0.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.14
Enterprise Value/Ebitda-0.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)$18.98M
Bulls Say, Bears Say
Bulls Say
Immunotherapy FocusA focused immunotherapy platform gives Cel-Sci exposure to a specialized biotechnology segment addressing serious diseases. Its emphasis on activating or modulating the immune system provides a coherent scientific direction and preserves potential upside if development efforts achieve clinical and regulatory success.
Diversified Operating ModelThe CDMO operation adds a second business capability alongside the internal Multikine program, broadening the company’s strategic base beyond a single investigational asset. Biologics development and manufacturing expertise may also support organizational capabilities relevant to future product development.
Historically Moderate LeverageHistorically moderate leverage and positive equity indicate that Cel-Sci had not relied on excessive debt during earlier development periods. This provided more financial flexibility than a highly leveraged biotechnology structure, although the recent TTM balance-sheet change materially weakens the consistency of that advantage.
Bears Say
No Commercial RevenueZero reported revenue confirms that Cel-Sci remains pre-commercial and has not yet demonstrated customer demand or product monetization. Without an established sales base, future funding and operating progress depend heavily on development execution and eventual commercialization rather than internally generated business income.
Persistent Losses And Cash BurnRecurring losses and negative operating and free cash flow show that the business is not self-funding. Continued development therefore consumes capital before commercial revenue is available, increasing dependence on future financing and making sustained profitability contingent on successful clinical and business execution.
Balance-sheet VolatilityThe sharp TTM step-up in reported debt, assets, and equity creates substantial uncertainty around the company’s capital structure and funding profile. Even with TTM debt-to-equity near 0.72, the magnitude of the change is a significant volatility flag that complicates assessment of financial stability.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $0.89 and its highest was $9.35 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $28.85M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is Dec 23, 2026 which is in 58 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Aug 17, 2026. The company reported -$0.47 earnings per share for the quarter.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 17,588,987 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.47 in its last earnings report. Following the earnings report the stock price went up 0.649%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Technical Analysis
Ownership Overview
4.17% Insiders
1.83% Mutual Funds
<0.01% Other Institutional Investors
90.74% Public Companies and
Individual Investors